Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep 17:5:21.
doi: 10.1186/1742-6405-5-21.

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

Shannon Schrader  1 , Susan K Chuck, Laurie W Rahn, Paras Parekh, Katherine G Emrich
Affiliations

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

Shannon Schrader et al. AIDS Res Ther. .

Abstract

Background: The tablet formulation of ritonavir-boosted lopinavir (LPV/r; Kaletra) has many advantages over the soft gel capsule (SGC) formulation, including lower pill count, no refrigeration requirement, and no dietary restrictions. These advantages may help improve patient compliance and therefore increase adherence to treatment. However, there are limited data regarding patient preferences and only recently was the comparative efficacy and tolerability data of LPV/r SGC versus tablet formulation presented at an international conference. To address this deficit, we conducted a market research survey to assess potential tolerability benefits, patient satisfaction, changes in adherence, and formulation preference in patients switching from SGCs to the tablet formulation. Data from 332 patients who switched from LPV/r SGCs twice-daily (BID) to tablets BID and 41 patients who switched from LPV/r SGCs BID or once daily (QD) to tablets QD were analyzed.

Results: Switching from SGCs to a tablet formulation of LPV/r was associated with increased patient satisfaction, tolerability and self-reported adherence to treatment; gastrointestinal side effects were reduced. In addition, respondents indicated that they preferred the tablet formulation to the SGC.

Conclusion: The LPV/r tablet formulation provides HIV-infected patients with multiple benefits over the SGC in terms of tolerability and convenience. Additional assessments to further define the tolerability profile of the LPV/r tablet, including studies using once-daily dosing, are warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tolerability reported by respondents switched to tablets BID or QD.
Figure 2
Figure 2
Reasons for non-adherence in patients switched from SGCs BID to tablets BID.
See this image and copyright information in PMC

References

    1. Murphy R, da Silva B, McMillan F, Hicks C, Eron J, Wolfe P, Gulick R, Glesby M, Thompson M, Benson C, White A, Albrecht M, Kessler H, Niemi K, King K, Calhoun D, King M, Hanna G, Brun S. Seven year follow-up of a lopinavir/ritonovir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects. 10th EACS, Dublin, Ireland November 17–20, 2005 [Poster PE79/3]
    1. Pau AK, Moodley NK, Holland DT, Fomundam H, Matchaba GU, Capparelli EV. Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines. AIDS. 2005;19:1233–1234. doi: 10.1097/01.aids.0000176227.01850.9e. - DOI - PubMed
    1. Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, Breitenbach J, Morris JB, Brun SC, Hanna GJ. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007;44:401–410. doi: 10.1097/QAI.0b013e31803133c5. - DOI - PubMed
    1. Klein C, Chiu Y, Cai Y, Beck K, King KR, Causemaker SJ, Doan T, Esslinger HU, Podsadecki TJ, Hanna G. Lack of effect of acid reducing agents on pharmacokinetics (PK) of lopinavir/ritonovir (LPV/r) tablet formulation. 13th CROI, Denver, CO; February 5–8 2006 [Poster L-1003]
    1. Gathe J, da Silva BA, Loutfy M, Podzamczer D, Rubio R. Study M05-730 Primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily versus twice daily co-administered with tenofovir DF + emtricitabine in antiretroviral-naive HIV-infected subjects. 15th CROI, Boston, MA; February 3–6, 2008 [Poster 775]

LinkOut - more resources